Table 2.
Newer drug classes and extent of development for T2DM patients
| Drug class | Molecule/drug name | Highest phase of development reached | Current status |
|---|---|---|---|
| PPAR-γ agonists/modulators | Inlacin (DLBS 3233) | Philippines FDA approved | Marketed |
| Balaglitazone | Phase 3 | Development halted | |
| PPAR-α/γ co-agonists | Lobeglitazone (CDK-501) | Korea FDA approved | Marketed |
| Aleglitazar | Phase 3 | Development stopped | |
| PPAR pan-agonists | Chiglitazar | Phase 3 | Under development |
| Dual SGLT1/SGLT2 inhibitor | Sotagliflozin (LX4211) | Completed phase 2 | Phase 3 planning |
| Glimins | Imeglimin | Phase 2 | Phase 3 planning |
| Anti-inflammatory agents | Diacerin | Phase 3 | Under development |
| Canakinumab | Phase 3 | Development stopped | |
| Salsalate | Phase 3 | Development stopped | |
| Glucokinase activators | Various molecules | Phase 2 | Early phase |
| G-protein coupled receptor (GPCR/GPR) agonists | TAK-875 | Phase 3 | Development discontinued |
| JTT851 and DS-8500 | Phase 2 | Under development | |
| Hybrid peptide agonists | (TT401/LY2944876) | Phase 2 | Under development |
| Apical sodium-dependent bile acid transporter (ASBT) inhibitors | GSK672 (GSK2330672) | Phase 2 | Under development |
| Glucagon receptor (GCGR) antagonists | GCGRx (Isis) | Phase 2 (NCT01885260) | Under development |
| MK-3577, LY-2409021/Adomeglivant and PF06291874 | Phase 2 (NCT00868790, NCT02111096 and NCT02554877) | Development discontinued | |
| Mitochondrial target of thiazolidinediones (mTOT agonists) | MSDC 0160 and MSDC 0602 | Phase 2 | Development discontinued |
| Fructose-1, 6-bisphosphatase (FBPase) inhibitors | MB07803 | Phase 2 | Under development |
| Diacylglycerolacyl transferase (DGAT)-1 Inhibitors | P7435 | Phase 1 | No recent updates |
| 11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) Inhibitors | INB13739 and MK0916 | Phase 2 (NCT 00543595 and NCT00698230) | No recent updates |
| Cannabinoid receptor antagonists | GWP42004 | Phase 2 | Under development |
| Glucocorticoid receptor antagonist | IONIS-GCCRRx | Phase 2 | Under development |
| HSP (heat shock protein) inducer | BGP-15 | Phase 2 | Under development |
| Protein tyrosine phosphatise 1B (PTP1B) inhibitors | IONIS-PTP1BRx | Phase 2 | Under development |